Unsupervised domain adaptation (UDA) aims at reducing the distribution discrepancy when transferring knowledge from a labeled source domain to an unlabeled target domain. Previous UDA methods assume that the source and target domains share an identical label space, which is unrealistic in practice since the label information of the target domain is agnostic. This article focuses on a more realistic UDA scenario, i.e., partial domain adaptation (PDA), where the target label space is subsumed to the source label space. In the PDA scenario, the source outliers that are absent in the target domain may be wrongly matched to the target domain (technically named negative transfer), leading to performance degradation of UDA methods. This article proposes a novel target-domain-specific classifier learning-based domain adaptation (TSCDA) method. TSCDA presents a soft-weighed maximum mean discrepancy criterion to partially align feature distributions and alleviate negative transfer. Also, it learns a target-specific classifier for the target domain with pseudolabels and multiple auxiliary classifiers to further address the classifier shift. A module named peers-assisted learning is used to minimize the prediction difference between multiple target-specific classifiers, which makes the classifiers more discriminant for the target domain. Extensive experiments conducted on three PDA benchmark data sets show that TSCDA outperforms other state-of-the-art methods with a large margin, e.g., 4% and 5.6% averagely on Office-31 and Office-Home, respectively.

Download full-text PDF

Source
http://dx.doi.org/10.1109/TNNLS.2020.2995648DOI Listing

Publication Analysis

Top Keywords

target domain
24
domain adaptation
16
label space
12
domain
11
target-domain-specific classifier
8
partial domain
8
target
8
uda methods
8
negative transfer
8
learning target-domain-specific
4

Similar Publications

N6-methyladenosine RNA modification regulates the transcription of SLC7A11 through KDM6B and GATA3 to modulate ferroptosis.

J Biomed Sci

January 2025

Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.

Background: Recent studies indicate that N6-methyladenosine (mA) RNA modification may regulate ferroptosis in cancer cells, while its molecular mechanisms require further investigation.

Methods: Liquid Chromatography-Tandem Mass Spectrometry (HPLC/MS/MS) was used to detect changes in mA levels in cells. Transmission electron microscopy and flow cytometry were used to detect mitochondrial reactive oxygen species (ROS).

View Article and Find Full Text PDF

Biarsenical-based fluorescent labeling of metallothioneins as a method for ultrasensitive quantification of poly-Cys targets.

Anal Chim Acta

February 2025

Department of Chemical Biology, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, 50-383, Wrocław, Poland. Electronic address:

Background: Mammalian metallothioneins (MTs) play a crucial role in maintaining Zn(II) and Cu(I) homeostasis, as well as regulating the cellular redox potential. They are involved in cancer resistance to cisplatin-related drugs and the sequestration of toxic metal ions. To investigate their participation in specific physiological and pathological processes, it is imperative to develop an analytical method for measuring changes in protein concentration both in vitro and in vivo.

View Article and Find Full Text PDF

Background: Mutations in the structural domain of the epidermal growth factor receptor (EGFR) kinase represent a critical pathogenetic factor in non-small cell lung cancer (NSCLC). Small-molecule EGFR-tyrosine kinase inhibitors (TKIs) serve as first-line therapeutic agents for the treatment of EGFR-mutated NSCLC. But the resistance mutations of EGFR restrict the clinical application of EGFR-TKIs.

View Article and Find Full Text PDF

Background: SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG-derived Fc domain. In preclinical studies, a murine equivalent SIRPα-Fc-CD40L fusion protein provided superior antitumor immunity in comparison to CD47- and CD40-targeted antibodies. A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.

View Article and Find Full Text PDF

In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition.

J Mol Graph Model

January 2025

School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; Department of Health Sciences, University of York, York, YO10 5DD, UK. Electronic address:

The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!